Eagle Pharmaceuticals Inc (EGRX)
0.6503
-0.05
(-7.17%)
USD |
OTCM |
Nov 15, 16:00
Eagle Pharmaceuticals Research and Development Expense (TTM): 35.65M for June 30, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2023 | 35.65M |
| March 31, 2023 | 37.25M |
| December 31, 2022 | 34.09M |
| September 30, 2022 | 30.66M |
| June 30, 2022 | 44.62M |
| March 31, 2022 | 43.10M |
| December 31, 2021 | 51.28M |
| September 30, 2021 | 56.88M |
| June 30, 2021 | 38.42M |
| March 31, 2021 | 35.65M |
| December 31, 2020 | 30.78M |
| September 30, 2020 | 32.70M |
| June 30, 2020 | 38.04M |
| March 31, 2020 | 39.86M |
| December 31, 2019 | 36.81M |
| September 30, 2019 | 31.36M |
| June 30, 2019 | 27.17M |
| March 31, 2019 | 33.47M |
| December 31, 2018 | 44.42M |
| September 30, 2018 | 48.00M |
| Date | Value |
|---|---|
| June 30, 2018 | 50.98M |
| March 31, 2018 | 42.40M |
| December 31, 2017 | 32.61M |
| September 30, 2017 | 37.84M |
| June 30, 2017 | 32.09M |
| March 31, 2017 | 29.21M |
| December 31, 2016 | 27.20M |
| September 30, 2016 | 21.31M |
| June 30, 2016 | 25.01M |
| March 31, 2016 | 27.09M |
| December 31, 2015 | 27.86M |
| September 30, 2015 | 23.06M |
| June 30, 2015 | 22.04M |
| March 31, 2015 | 20.70M |
| December 31, 2014 | 18.21M |
| September 30, 2014 | 16.82M |
| June 30, 2014 | 14.35M |
| March 31, 2014 | 11.43M |
| December 31, 2013 | 10.17M |
| September 30, 2013 | 9.795M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
30.66M
Minimum
Sep 2022
56.88M
Maximum
Sep 2021
39.05M
Average
37.25M
Median
Mar 2023
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| Verrica Pharmaceuticals Inc | 15.99M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |